Tags

Type your tag names separated by a space and hit enter

Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Eur Respir J. 2005 Dec; 26(6):1086-91.ER

Abstract

The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002. A prospective cohort study was conducted including all individuals>or=65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n=11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status. Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50-1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56-1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09-0.83). In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly.

Authors+Show Affiliations

EVAN-65 Group of Primary Care Service Tarragona-Valls, Institut Català de la Salut, Prat de la Riba 39, Tarragona 43001, Spain. avila.tarte.ics@gencat.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16319340

Citation

Vila-Córcoles, A, et al. "Protective Effect of Pneumococcal Vaccine Against Death By Pneumonia in Elderly Subjects." The European Respiratory Journal, vol. 26, no. 6, 2005, pp. 1086-91.
Vila-Córcoles A, Ochoa-Gondar O, Llor C, et al. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J. 2005;26(6):1086-91.
Vila-Córcoles, A., Ochoa-Gondar, O., Llor, C., Hospital, I., Rodríguez, T., & Gómez, A. (2005). Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. The European Respiratory Journal, 26(6), 1086-91.
Vila-Córcoles A, et al. Protective Effect of Pneumococcal Vaccine Against Death By Pneumonia in Elderly Subjects. Eur Respir J. 2005;26(6):1086-91. PubMed PMID: 16319340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. AU - Vila-Córcoles,A, AU - Ochoa-Gondar,O, AU - Llor,C, AU - Hospital,I, AU - Rodríguez,T, AU - Gómez,A, PY - 2005/12/2/pubmed PY - 2006/4/14/medline PY - 2005/12/2/entrez SP - 1086 EP - 91 JF - The European respiratory journal JO - Eur Respir J VL - 26 IS - 6 N2 - The present study assessed the effectiveness of the 23-valent pneumococcal polysaccharide vaccine to prevent pneumonia and death in older adults in a first-time report between January and December 2002. A prospective cohort study was conducted including all individuals>or=65 yrs of age assigned to one of eight primary care centres in Tarragona, Spain (n=11,241). The primary outcomes were community-acquired pneumonia (hospitalised or outpatient) and death from pneumonia. All pneumonias were validated by checking clinical records. The association between the pneumococcal vaccination and the risk of each outcome was evaluated by means of multivariate Cox proportional-hazard models, adjusted by age, sex, influenza vaccination status, comorbidity and immunological status. Pneumococcal vaccination did not alter the risk of hospitalisation from pneumonia (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.50-1.28) or overall pneumonia (HR: 0.86; 95% CI: 0.56-1.31), but the vaccine was associated with considerable reductions of death risk from pneumonia (HR: 0.28; 95% CI: 0.09-0.83). In conclusion, these results suggest that pneumococcal polysaccharide vaccine may not be effective in reducing the incidence of pneumonia, but may be able to diminish the severity of the infection. These findings support the effectiveness of the pneumococcal polysaccharide vaccine to prevent mortality caused by pneumonia in older adults, providing a new argument to recommend systematic vaccination in the elderly. SN - 0903-1936 UR - https://www.unboundmedicine.com/medline/citation/16319340/Protective_effect_of_pneumococcal_vaccine_against_death_by_pneumonia_in_elderly_subjects_ L2 - http://erj.ersjournals.com/cgi/pmidlookup?view=long&pmid=16319340 DB - PRIME DP - Unbound Medicine ER -